CGP37157 [75450-34-9]
Cat# T14941-50mg
Size : 50mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
CGP37157
(Synonyms: 7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepine-2(3H)-one) Copy Product Info
CGP37157 (7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepine-2(3H)-one) is a Na+/Ca2+ exchanger inhibitor, inhibits Na+-induced Ca2+ release from mitochondria in guinea pig heart with IC50 of 0.8 μM.
Cas No. 75450-34-9
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.92%
Appearance:Liquid
Color:White
COA HPLC LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CGP37157 (7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepine-2(3H)-one) is a Na+/Ca2+ exchanger inhibitor, inhibits Na+-induced Ca2+ release from mitochondria in guinea pig heart with IC50 of 0.8 μM. |
| Targets & IC50 | Na+, Ca2+ exchanger:0.8 μM |
| In vitro | Administration of 10?μM CGP37157 shows an inhibitory effect on mitochondrial Na+/Ca2+ exchanger in cortical neurons, modulating intracellular Ca2+ levels via suppressing voltage-gated calcium channels. Administration of 10?μM CGP37157 in combination with salinomycin significantly attenuates cell viability and increases apoptosis of FaDu and HLaC79 cells. CGP37157 has no inhibitory effect on salinomycin tumor toxicity[2]. Administration of 10?μM CGP37157 reduces NMDA-induced cytosolic and mitochondrial Ca2+ overloads and it also reduces NMDA-induced excitotoxicity, and such an effect is via attenuating mitochondrial damage and calpain activity in neurons[3]. |
| Synonyms | 7-Chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepine-2(3H)-one |
| Molecular Weight | 324.22 |
| Formula | C15H11Cl2NOS |
| Cas No. | 75450-34-9 |
| Smiles | Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1 |
| Relative Density. | 1.384 g/cm3 (Predicted) |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (462.65 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: < 10 mg/mL (30.84 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Corn oil: 10 mg/mL (30.84 mM), Solution. 10% DMSO+90% Saline: < 10 mg/mL (30.84 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% (20% SBE-β-CD in Saline): < 10 mg/mL (30.84 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||